These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Author: Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattnig S, Vécsei V.
    Journal: Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403.
    Abstract:
    PURPOSE: To compare the efficacy of extended-duration thromboprophylaxis with enoxaparin for 20 days in the outpatient setting with in-hospital thromboprophylaxis with enoxaparin (3 to 8 days) only in patients who had undergone arthroscopic surgery of the anterior cruciate ligament (ACL). METHODS: This was a single-center, randomized, double-blind, prospective trial investigating 175 ACL surgery patients. All patients received subcutaneous enoxaparin 40 mg once daily 12 to 18 hours presurgery and 3 to 8 days postsurgery during hospitalization. After discharge, patients were randomized to 40 mg enoxaparin (n = 87) or placebo (n = 88) self-administered once daily subcutaneously for 20 days. The primary efficacy end-points were the incidences of symptomatic and asymptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Primary safety endpoints were the incidences of major and minor bleeding. RESULTS: Thirty-five patients were excluded because of noncompliance with the predefined protocol. No patient had DVT confirmed by magnetic resonance venography (MRV) at discharge. Of 140 patients in the intention-to-treat population, 2 (2.8%) who received postdischarge enoxaparin (n = 72) and 28 (41.2%) who received placebo (n = 68) had DVT confirmed by MRV (P < .001). No patients were diagnosed with PE. No major bleeds occurred. Minor bleeding occurred in 13 (2.5%) out of 513 postdischarge enoxaparin injections and 10 (2.0%) out of 492 placebo injections (P = .595). Risk factors for DVT during the 20 days postdischarge were age >30 years (odds ratio [OR]: 3.241; 95% confidence interval [CI], 1.015 to 10.349) and immobilization before surgery (OR 18.195; 95% CI, 2.046 to 161.837). CONCLUSIONS: Extended-duration postdischarge thromboprophylaxis for 20 days with enoxaparin in the outpatient setting significantly reduced the incidence of DVT in ACL surgery patients compared with enoxaparin limited to in-hospital thromboprophylaxis without increasing major or minor bleeding. LEVEL OF EVIDENCE: Level I, high-quality randomized controlled trial.
    [Abstract] [Full Text] [Related] [New Search]